One-Year Pharmacovigilance Update of Brodalumab

J Drugs Dermatol. 2020 Aug 1;19(8):807-808. doi: 10.36849/JDD.2020.5138.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / pharmacokinetics
  • Arthralgia / chemically induced
  • Arthralgia / epidemiology
  • Arthralgia / immunology
  • Depression / chemically induced
  • Depression / epidemiology
  • Depression / immunology
  • Diarrhea / chemically induced
  • Diarrhea / epidemiology
  • Diarrhea / immunology
  • Drug Monitoring / statistics & numerical data*
  • Half-Life
  • Humans
  • Pharmacovigilance
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Receptors, Interleukin-17 / antagonists & inhibitors
  • Receptors, Interleukin-17 / immunology
  • Time Factors
  • United States / epidemiology

Substances

  • Antibodies, Monoclonal, Humanized
  • IL17RA protein, human
  • Receptors, Interleukin-17
  • brodalumab